DE69434593D1 - Verfahren und zusammensetzungen zur stimulation und inhibition der aktivität von tgf-beta - Google Patents
Verfahren und zusammensetzungen zur stimulation und inhibition der aktivität von tgf-betaInfo
- Publication number
- DE69434593D1 DE69434593D1 DE69434593T DE69434593T DE69434593D1 DE 69434593 D1 DE69434593 D1 DE 69434593D1 DE 69434593 T DE69434593 T DE 69434593T DE 69434593 T DE69434593 T DE 69434593T DE 69434593 D1 DE69434593 D1 DE 69434593D1
- Authority
- DE
- Germany
- Prior art keywords
- beta
- tgf
- latent
- effective
- inhibiting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title abstract 18
- 238000000034 method Methods 0.000 title abstract 6
- 230000002401 inhibitory effect Effects 0.000 title abstract 5
- 230000000694 effects Effects 0.000 title abstract 3
- 230000004936 stimulating effect Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 17
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 17
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 206010016654 Fibrosis Diseases 0.000 abstract 3
- 238000006243 chemical reaction Methods 0.000 abstract 3
- 230000004761 fibrosis Effects 0.000 abstract 3
- 230000003213 activating effect Effects 0.000 abstract 2
- 210000002889 endothelial cell Anatomy 0.000 abstract 2
- 230000029663 wound healing Effects 0.000 abstract 2
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000010046 negative regulation of endothelial cell proliferation Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10612093A | 1993-08-13 | 1993-08-13 | |
| US23816994A | 1994-05-04 | 1994-05-04 | |
| PCT/US1994/009193 WO1995005191A1 (en) | 1993-08-13 | 1994-08-12 | METHODS AND COMPOSITIONS FOR STIMULATING AND INHIBITING TGF-β ACTIVITY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE69434593D1 true DE69434593D1 (de) | 2006-02-02 |
Family
ID=26803316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69434593T Expired - Lifetime DE69434593D1 (de) | 1993-08-13 | 1994-08-12 | Verfahren und zusammensetzungen zur stimulation und inhibition der aktivität von tgf-beta |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6384189B1 (de) |
| EP (1) | EP0716609B1 (de) |
| JP (1) | JPH09505555A (de) |
| AT (1) | ATE314394T1 (de) |
| AU (1) | AU697624B2 (de) |
| CA (1) | CA2169360A1 (de) |
| DE (1) | DE69434593D1 (de) |
| WO (1) | WO1995005191A1 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0918795T3 (da) * | 1997-03-17 | 2005-03-14 | Abbott Lab | Antiangiogene lægemidler til behandling af cancer, arthritis og retinopati |
| US5932545A (en) * | 1997-03-17 | 1999-08-03 | Abbott Laboratories | Antiangiogenic drug to treat cancer, arthritis and retinopathy |
| CA2240607A1 (en) | 1997-08-13 | 1999-02-13 | Kyowa Hakko Kogyo Co., Ltd. | Novel vascular smooth muscle cell growth factor |
| US7067117B1 (en) | 1997-09-11 | 2006-06-27 | Cambridge University Technical Services, Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
| US6989435B2 (en) | 1997-09-11 | 2006-01-24 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
| US6121236A (en) | 1998-03-24 | 2000-09-19 | The Children's Medical Center Corporation | Multivalent ligands which modulate angiogenesis |
| US7238711B1 (en) | 1999-03-17 | 2007-07-03 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
| AU2610000A (en) * | 1999-01-12 | 2000-08-01 | Cambridge University Technical Services Limited | Compounds and methods to inhibit or augment an inflammatory response |
| GB9915311D0 (en) * | 1999-06-30 | 1999-09-01 | Isis Innovation | Modulation of dendritic cell maturation |
| ITMI20010995A1 (it) | 2001-05-15 | 2002-11-15 | Getters Spa | Dispensatori di cesio e processo per il loro uso |
| US7223390B2 (en) * | 2003-05-09 | 2007-05-29 | Research Development Foundation | Insertion of furin protease cleavage sites in membrane proteins and uses thereof |
| EA200800123A1 (ru) * | 2005-06-24 | 2008-12-30 | Кадила Хелзкэр Лимитед | Пептиды, производные тромбоспондина-1, и способы лечения |
| US9614220B2 (en) | 2007-01-29 | 2017-04-04 | Umicore | Doped and island-covered lithium cobaltite oxides |
| WO2010017332A2 (en) * | 2008-08-07 | 2010-02-11 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services | Radioprotectants targeting thrombospondin-1 and cd47 |
| AU2013246040B2 (en) | 2012-04-09 | 2018-11-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for generation of pluripotent and multipotent cells |
| KR101594032B1 (ko) * | 2012-08-23 | 2016-02-15 | 강원대학교산학협력단 | 염증 또는 피부노화의 예방 또는 치료용 약학 조성물 및 염증 또는 피부노화 개선용 화장료 조성물 |
| WO2014160183A1 (en) | 2013-03-13 | 2014-10-02 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Methods for modulating chemotherapeutic cytotoxicity |
| BR112015027569A2 (pt) * | 2013-05-10 | 2017-09-19 | Southern Res Inst | compostos, composições, métodos e respectivos usos para tratar doenças por meio da inibição da atividade de tgf-ß |
| FR3024364B1 (fr) | 2014-07-31 | 2016-09-02 | Neuronax | Oligopeptides particuliers comme medicaments anti-angiogeniques |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2085865T3 (es) * | 1988-06-30 | 1996-06-16 | Astra Ab | Analogos de dermorfina, sus metodos de preparacion, composiciones farmaceuticas, y metodos de tratamiento terapeutico que los emplean. |
| US5028425A (en) * | 1988-07-07 | 1991-07-02 | The United States Of America As Represented By The Department Of Health And Human Services | Synthetic vaccine against P. falciparum malaria |
| US5192744A (en) | 1990-01-12 | 1993-03-09 | Northwestern University | Method of inhibiting angiogenesis of tumors |
| US5190918A (en) | 1990-02-22 | 1993-03-02 | W. R. Grace & Co.-Conn. | Peptide fragments and analogs of thrombospondin and methods of use |
| US5674503A (en) * | 1990-07-24 | 1997-10-07 | University Of Victoria | Peptides capable of eliciting an immune response to leishmaniasis and methods of using the same |
| US5824647A (en) * | 1990-12-12 | 1998-10-20 | Postlethwaite; Arnold E. | Chemotactic wound healing peptides |
| US5357041A (en) * | 1991-12-06 | 1994-10-18 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Heparin- and sulfatide-binding peptides from the type I repeats of human thrombospondin |
| US5770563A (en) * | 1991-12-06 | 1998-06-23 | The United States Of America As Represented By The Department Of Health And Human Services | Heparin- and sulfatide binding peptides from the type I repeats of human thrombospondin and conjugates thereof |
| EP0673384A4 (de) * | 1992-12-10 | 1996-10-09 | Univ Minnesota | Polypeptide nützlich in der behandlung von entzündlichen erkrankungen. |
| US5561107A (en) * | 1993-06-04 | 1996-10-01 | Demeter Biotechnologies, Ltd. | Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides |
-
1994
- 1994-08-12 EP EP94925878A patent/EP0716609B1/de not_active Expired - Lifetime
- 1994-08-12 AU AU75652/94A patent/AU697624B2/en not_active Ceased
- 1994-08-12 CA CA002169360A patent/CA2169360A1/en not_active Abandoned
- 1994-08-12 AT AT94925878T patent/ATE314394T1/de not_active IP Right Cessation
- 1994-08-12 JP JP7507120A patent/JPH09505555A/ja not_active Ceased
- 1994-08-12 DE DE69434593T patent/DE69434593D1/de not_active Expired - Lifetime
- 1994-08-12 WO PCT/US1994/009193 patent/WO1995005191A1/en active IP Right Grant
-
1997
- 1997-06-10 US US08/871,561 patent/US6384189B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU7565294A (en) | 1995-03-14 |
| EP0716609A4 (de) | 1998-01-07 |
| CA2169360A1 (en) | 1995-02-23 |
| ATE314394T1 (de) | 2006-01-15 |
| US6384189B1 (en) | 2002-05-07 |
| EP0716609B1 (de) | 2005-12-28 |
| JPH09505555A (ja) | 1997-06-03 |
| WO1995005191A1 (en) | 1995-02-23 |
| AU697624B2 (en) | 1998-10-15 |
| EP0716609A1 (de) | 1996-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69434593D1 (de) | Verfahren und zusammensetzungen zur stimulation und inhibition der aktivität von tgf-beta | |
| DE69636997D1 (de) | HEILUNG UND VORBEUGUNG VON DURCH NF-kappaB VERURSACHTEN ERKRANKUNGEN | |
| ES2082198T3 (es) | Inhibidores de esteroide-sulfatasa. | |
| ATE529109T1 (de) | Hemmung der p38 kinase aktivität durch substituierte heterocyclische harnstoffe | |
| ATE241358T1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
| DE69429450D1 (de) | Die verwendung von angiotensin iii und seiner analoge für die gewebeheilung | |
| DE60029799D1 (de) | Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe | |
| ATE277612T1 (de) | Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen | |
| DE69836563D1 (de) | INHIBIERUNG DER p38 KINASE-AKTIVITÄT DURCH DIE VERWENDUNG VON ARYL- UND HETEROARYLSUBSTITUIERTEN HARNSTOFFEN | |
| ATE347366T1 (de) | Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen | |
| ATE413179T1 (de) | Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden | |
| ATE287717T1 (de) | Verwendung eines oestrogens zur verhütung und behandlung von ischaemischer schädigung | |
| DE69533704D1 (de) | Bradykinin-antagonist peptide mit n-substituierten glycinen | |
| DE69833937D1 (de) | Verwendung von zinkhyaluronat gegen magengeschwür | |
| ATE217514T1 (de) | Verwendung von bradykininantagonisten zur induzierung oder stimulation des haarwachstums und/oder zur verlangsamung des haarausfalls | |
| ATE453402T1 (de) | Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis | |
| ATE226084T1 (de) | Wundheilung und behandlung von fibrose | |
| DE69625682D1 (de) | Verfahren zur behandlung von entzündungen und zusammensetzungen dafür | |
| IS4847A (is) | Aðferð til meðferðar gegn hjartabilun þar sem notuð eru mótlyf gegn endóþelíni | |
| DK0671909T3 (da) | Syndecanstimulering af cellulær differentiering | |
| DE69924979D1 (de) | Behandlung von chronischen schmerzen | |
| ATE210989T1 (de) | Zusammensetzung und verfahren zur stimulation der reproduzierenden leistung | |
| ATE208202T1 (de) | Verwendung von dimeticon zur behandlung der konstipation | |
| ATE302023T1 (de) | Verwendung von stickstoffoxid zur behandlung von atemwegs-verengungen | |
| ATE216885T1 (de) | Verwendung von penciclovir zur behandlung von postherpetischer neuralgie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8332 | No legal effect for de |